These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 10209699)

  • 1. Mizolastine: antihistaminic activity from preclinical data to clinical evaluation.
    Simons FE
    Clin Exp Allergy; 1999 Mar; 29 Suppl 1():3-8. PubMed ID: 10209699
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetic and pharmacodynamic modeling of mizolastine in healthy volunteers with an indirect response model.
    Deschamps C; Dubruc C; Mentre F; Rosenzweig P
    Clin Pharmacol Ther; 2000 Dec; 68(6):647-57. PubMed ID: 11180025
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacodynamics and pharmacokinetics of mizolastine (SL 85.0324), a new nonsedative H1 antihistamine.
    Rosenzweig P; Thebault JJ; Caplain H; Dubruc C; Bianchetti G; Fuseau E; Morselli PL
    Ann Allergy; 1992 Aug; 69(2):135-9. PubMed ID: 1354949
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative wheal and flare study of mizolastine vs terfenadine, cetirizine, loratadine and placebo in healthy volunteers.
    Rosenzweig P; Caplain H; Chaufour S; Ulliac N; Cabanis MJ; Thebault JJ
    Br J Clin Pharmacol; 1995 Nov; 40(5):459-65. PubMed ID: 8703650
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical pharmacokinetics of mizolastine.
    Lebrun-Vignes B; Diquet B; Chosidow O
    Clin Pharmacokinet; 2001; 40(7):501-7. PubMed ID: 11510627
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-inflammatory properties of mizolastine after oral administration on arachidonic acid-induced cutaneous reaction in the rat.
    Pichat P; Angel I; Arbilla S
    Arzneimittelforschung; 1998 Feb; 48(2):173-8. PubMed ID: 9541729
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Comparative activity of antihistamines on area under dose-response curve from histamine-induced wheal and flare responses in human skin].
    Wang RQ; Zhang HY
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2004 Dec; 26(6):634-8. PubMed ID: 15663222
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Plasma and skin suction-blister-fluid pharmacokinetics and time course of the effects of oral mizolastine.
    Chosidow O; Dubruc C; Danjou P; Fuseau E; Espagne E; Bianchetti G; Thenot JP; Herson S; Rosenzweig P; Revuz J
    Eur J Clin Pharmacol; 1996; 50(4):327-33. PubMed ID: 8803528
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lack of subsensitivity to mizolastine over 8-week treatment.
    Bousquet J; Chanal I; Murrieta M; Stalla-Bourdillon A
    Allergy; 1996 Apr; 51(4):251-6. PubMed ID: 8792922
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The comparative pharmacokinetics of H1-receptor antagonists.
    Simons FE; Simons KJ; Chung M; Yeh J
    Ann Allergy; 1987 Dec; 59(6 Pt 2):20-4. PubMed ID: 2892445
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A pharmacokinetic-pharmacodynamic modelling of the antihistaminic (H1) effects of cetirizine.
    Urien S; Tillement JP; Ganem B; Kuch MD
    Int J Clin Pharmacol Ther; 1999 Oct; 37(10):499-502. PubMed ID: 10543317
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of histamine-induced skin wheal and flare after 5 days of mizolastine.
    Pinquier JL; Caplain H; Cabanis MJ; Dubruc C; Stalla-Bourdillon A; Rosenzweig P
    J Clin Pharmacol; 1996 Jan; 36(1):72-8. PubMed ID: 8932546
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative therapeutic effect and safety of mizolastine and loratadine in chronic idiopathic urticaria. URTILOR study group.
    Leynadier F; Duarte-Risselin C; Murrieta M
    Eur J Dermatol; 2000; 10(3):205-11. PubMed ID: 10725819
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Study of cardiac repolarization in healthy volunteers performed with mizolastine, a new H1-receptor antagonist.
    Chaufour S; Caplain H; Lilienthal N; L'héritier C; Deschamps C; Dubruc C; Rosenzweig P
    Br J Clin Pharmacol; 1999 May; 47(5):515-20. PubMed ID: 10336575
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ebastine in allergic rhinitis and chronic idiopathic urticaria.
    Sastre J
    Allergy; 2008 Dec; 63 Suppl 89():1-20. PubMed ID: 19032340
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative activity of cetirizine and mizolastine on histamine-induced skin wheal and flare responses at 24 h.
    Purohit A; Mélac M; Pauli G; Frossard N
    Br J Clin Pharmacol; 2002 Mar; 53(3):250-4. PubMed ID: 11874388
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Astemizole: its pharmacokinetics and pharmacologic properties].
    Levron JC; Gillardin JM; Sabbah A
    Allerg Immunol (Paris); 1990 Jun; 22(6):233-41. PubMed ID: 1974137
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical pharmacology of new histamine H1 receptor antagonists.
    Simons FE; Simons KJ
    Clin Pharmacokinet; 1999 May; 36(5):329-52. PubMed ID: 10384858
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetic-pharmacodynamic modelling of the antihistaminic (H1) effect of bilastine.
    Jauregizar N; de la Fuente L; Lucero ML; Sologuren A; Leal N; Rodríguez M
    Clin Pharmacokinet; 2009; 48(8):543-54. PubMed ID: 19705924
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lack of interaction between a new antihistamine, mizolastine, and lorazepam on psychomotor performance and memory in healthy volunteers.
    Patat A; Perault MC; Vandel B; Ulliac N; Zieleniuk I; Rosenzweig P
    Br J Clin Pharmacol; 1995 Jan; 39(1):31-8. PubMed ID: 7756096
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.